Phase 3 Clinical Trials With Primary Completion Dates in December 2016
This is a list of Phase 3 trials with primary completion dates in December 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACOR | Acorda Therapeutics, Inc. | 2016-12-01 | Phase 3 | NCT02352363 | Randomized Safety Study of CVT-301 Compared to an Observational Control Group |
| ACOR | Acorda Therapeutics, Inc. | 2016-12-01 | Phase 3 | NCT02240030 | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes |
| AERI | Aerie Pharmaceuticals, Inc. | 2016-12-01 | Phase 3 | NCT02246764 | Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension |
| AEZS | AEterna Zentaris Inc. | 2016-12-01 | Phase 3 | NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer |
| ALKS | Alkermes plc | 2016-12-01 | Phase 3 | NCT02537574 | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension) |
| CMRX | Chimerix, Inc. | 2016-12-01 | Phase 3 | NCT02087306 | Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection |
| CTIC | CTI BioPharma Corp. | 2016-12-01 | Phase 3 | NCT01321541 | Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant |
| CYTR | CytRx Corporation | 2016-12-01 | Phase 3 | NCT02049905 | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas |
| DEPO | Depomed, Inc. | 2016-12-01 | Phase 3 | NCT02081391 | An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants |
| EARS | Auris Medical Holding AG | 2016-12-01 | Phase 3 | NCT02040207 | AM-101 in the Treatment of Post-Acute Tinnitus 2 |
| ENDP | Endo International plc | 2016-12-01 | Phase 3 | NCT02687451 | Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| ENDP | Endo International plc | 2016-12-01 | Phase 3 | NCT01210352 | Effectiveness, Safety, and Tolerability Study of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects |
| ENDP | Endo International plc | 2016-12-01 | Phase 3 | NCT00356213 | Comparison of Laparoscopic Sleeve Gastrectomy and Roux-Y-gastric Bypass in the Treatment of Morbid Obesity |
| EVOK | Evoke Pharma, Inc. | 2016-12-01 | Phase 3 | NCT02025751 | Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis |
| ICLR | ICON plc | 2016-12-01 | Phase 3 | NCT02547623 | Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery |
| IONS | Ionis Pharmaceuticals, Inc. | 2016-12-01 | Phase 3 | NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia |
| IONS | Ionis Pharmaceuticals, Inc. | 2016-12-01 | Phase 3 | NCT02211209 | The APPROACH Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome |
| LJPC | La Jolla Pharmaceutical Company | 2016-12-01 | Phase 3 | NCT02338843 | A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension |
| MESO | Mesoblast Limited | 2016-12-01 | Phase 3 | NCT00482092 | Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease |
| NBIX | Neurocrine Biosciences, Inc. | 2016-12-01 | Phase 3 | NCT02405091 | Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
| NLNK | NewLink Genetics Corporation | 2016-12-01 | Phase 3 | NCT01836432 | Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer |
| NVAX | Novavax, Inc. | 2016-12-01 | Phase 3 | NCT02608502 | A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults |
| NVCR | NovoCure Limited | 2016-12-01 | Phase 3 | NCT00916409 | Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
| OMER | Omeros Corporation | 2016-12-01 | Phase 3 | NCT02132312 | A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement |
| ONTX | Onconova Therapeutics, Inc. | 2016-12-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| PPHM | Peregrine Pharmaceuticals Inc. | 2016-12-01 | Phase 3 | NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer |
| PPHMP | Peregrine Pharmaceuticals Inc. | 2016-12-01 | Phase 3 | NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer |
| PRTO | Proteon Therapeutics, Inc. | 2016-12-01 | Phase 3 | NCT02110901 | A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1) |
| PRXL | PAREXEL International Corporation | 2016-12-01 | Phase 3 | NCT02319642 | An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044 |
| RDHL | Redhill Biopharma Ltd. | 2016-12-01 | Phase 3 | NCT02246439 | Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study) |
| RDY | Dr. Reddy's Laboratories Ltd | 2016-12-01 | Phase 3 | NCT02569853 | DFN-11 Injection in Episodic Migraine With or Without Aura |
| UTHR | United Therapeutics Corporation | 2016-12-01 | Phase 3 | NCT01560624 | Trial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial Hypertension |
| XBIT | XBiotech Inc. | 2016-12-01 | Phase 3 | NCT01767857 | A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer |